Andrew Huberman· PhD
They're not miracle drugs, right. They come with problems, right, which is, you know, they're catabolic across the board. So patients are losing fat, but they're losing muscle as well.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
They're not miracle drugs, right. They come with problems, right, which is, you know, they're catabolic across the board. So patients are losing fat, but they're losing muscle as well.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
with the concerns about gp1s the one I hear most is loss of lean mass so in studies people who use glp1 Medics they lose like 30 to 40% of the weight from lean mass which is a concern but by the way that is similar to the amount of weight from lean mass people use who diet without resistance training or exercise so I I don't think that it's a unique problem to glp wants
and my guess is when we start getting studies that combine exercise with gp1s and look at um lean mass retention we'll probably see pretty similar results